An Observational Retrospective Cohort Trial on 4,828 IVF Cycles Evaluating Different Low Prognosis Patients Following the POSEIDON Criteria

Paolo Emanuele Levi-Setti, Irene Zerbetto, Annamaria Baggiani, Elena Zannoni, Laura Sacchi, Antonella Smeraldi, Emanuela Morenghi, Raffaella De Cesare, Alessandra Drovanti, Daniele Santi, Paolo Emanuele Levi-Setti, Irene Zerbetto, Annamaria Baggiani, Elena Zannoni, Laura Sacchi, Antonella Smeraldi, Emanuela Morenghi, Raffaella De Cesare, Alessandra Drovanti, Daniele Santi

Abstract

Objective: To study the actual controlled ovarian stimulation (COS) management in women with suboptimal response, comparing clinical outcomes to the gonadotropins consume, considering potential role of luteinizing hormone (LH) addition to follicle-stimulating hormone (FSH). Design: Monocentric, observational, retrospective, real-world, clinical trial on fresh intra-cytoplasmic sperm injection (ICSI) cycles retrieving from 1 to 9 oocytes, performed at Humanitas Fertility Center from January 1st, 2012 to December 31st, 2015. Methods: COS protocols provided gonadotropin releasing-hormone (GnRH) agonist long, flare-up, short and antagonist. Both recombinant and urinary FSH were used for COS and LH was added according to the clinical practice. ICSI outcomes considered were: gonadotropins dosages; total, mature, injected and frozen oocytes; cumulative, transferred and frozen embryos; implantation rate; pregnancy, delivery and miscarriage rates. Outcomes were compared according to the gonadotropin regimen used during COS. Results: Our cohort showed 20.8% of low responders, defined as 1-3 oocytes retrieved and 79.2% of "suboptimal" responders, defined as 4-9 oocytes retrieved. According to recent POSEIDON stratification, cycles were divided in group 1 (6.9%), 2 (19.8%), 3 (11.7%), and 4 (61.5%). The cohort was divided in 3 groups, according to the gonadotropin's regimen. Women treated with FSH plus LH showed worst prognostic factors, in terms of age, basal FSH, AMH, and AFC. This difference was evident in suboptimal responders, whereas only AMH and AFC were different among treatment groups in low responders. Although a different result, in terms of oocytes and embryos detected, major ICSI outcomes (i.e., pregnancy and delivery rates) were similar among groups of COS treatment. Outcomes were significantly different among Poseidon groups. Implantation, pregnancy and delivery rates were significantly higher in Poseidon group 1 and progressively declined in other POSEIDON groups, reaching the worst percentage in group 4. Conclusions: In clinical practice, women with worst prognosis factors are generally treated with a combination of LH and FSH. Despite low prognosis women showed a reduced number of oocytes retrieved, the final ICSI outcome, in terms of pregnancy, is similarly among treatment group. This result suggests that the LH addition to FSH during COS could improve the quality of oocytes retrieved, balancing those differences that are evident at baseline. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT03290911.

Keywords: FSH; ICSI; LH; POSEIDON; suboptimal responders.

Figures

Figure 1
Figure 1
Study flow chart. *p<0.05.
Figure 2
Figure 2
Female age among groups of patients, divided according to gonadotropins regimen chosen.
Figure 3
Figure 3
Basal follicle stimulating hormone (FSH) serum levels among groups of patients, divided according to gonadotropins regimen chosen.
Figure 4
Figure 4
Anti-Mullerian hormone (AMH) among groups of patients, divided according to gonadotropins regimen chosen. *p<0.05.
Figure 5
Figure 5
Antral follicle count (AFC) among groups of patients, divided according to gonadotropins regimen chosen. *p<0.05.
Figure 6
Figure 6
Retrieved oocytes among groups of patients, divided according to gonadotropins regimen chosen.

References

    1. Giovanale V, Pulcinelli FM, Ralli E, Primiero FM, Caserta D. Poor responders in IVF: an update in therapy. Gynecol Endocrinol. (2015) 31:253–7. 10.3109/09513590.2014.987228
    1. Garcia JE, Jones GS, Acosta AA, Wright Jr G. Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration: phase II, 1981. Fertil Steril. (1983) 39:174–9. 10.1016/S0015-0282(16)46815-9
    1. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L. ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria. Hum Reprod. (2011) 26:1616–24. 10.1093/humrep/der092
    1. Humaidan P, Alviggi C, Fischer R, Esteves SC. The novel POSEIDON stratification of 'Low prognosis patients in Assisted Reproductive Technology' and its proposed marker of successful outcome. F1000Research. (2016) 5:2911. 10.12688/f1000research.10382.1
    1. Haahr T, Esteves SC, Humaidan P. Individualized controlled ovarian stimulation in expected poor-responders: an update. Reprod Biol Endocrinol. (2018) 16:20. 10.1186/s12958-018-0342-1
    1. Roque M, Bianco B, Christofolini DM, Barchi Cordts E, Vilarino F, Carvalho W, et al. . Pharmacogenetic algorithm for individualized controlled ovarian stimulation in assisted reproductive technology cycles. Panminerva Med. (2019) 61:76–81. 10.23736/S0031-0808.18.03496-1
    1. La Marca A, Sunkara SK. Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice. Hum Reprod Update. (2014) 20:124–40. 10.1093/humupd/dmt037
    1. Van Voorhis BJ, Thomas M, Surrey ES, Sparks A. What do consistently high-performing in vitro fertilization programs in the U.S. do? Fertil Steril. (2010) 94:1346–9. 10.1016/j.fertnstert.2010.06.048
    1. Santi D, Casarini L, Alviggi C, Simoni M. Response: commentary: efficacy of follicle-stimulating hormone (FSH) alone, FSH + luteinizing hormone, human menopausal gonadotropin or FSH + human chorionic gonadotropin on assisted reproductive technology outcomes in the “personalized” medicine era: a meta-analysis. Front Endocrinol (Lausanne). (2018) 9:113 10.3389/fendo.2018.00113
    1. Sunkara SK, LaMarca A, Polyzos NP, Seed PT, Khalaf Y. Live birth and perinatal outcomes following stimulated and unstimulated IVF: analysis of over two decades of a nationwide data. Hum Reprod. (2016) 31:2261–7. 10.1093/humrep/dew184
    1. Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, Esteves SC, et al. . A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil. Steril. (2016) 105:1452–3. 10.1016/j.fertnstert.2016.02.005
    1. Alviggi C, Conforti A, Esteves SC, Vallone R, Venturella R, Staiano S, et al. . Understanding ovarian hypo-response to exogenous gonadotropin in ovarian stimulation and its new proposed marker-the follicle-to-oocyte (FOI) index. Front Endocrinol (Lausanne). (2018) 9:589. 10.3389/fendo.2018.00589
    1. Esteves SC, Roque M, Bedoschi GM, Conforti A, Humaidan P, Alviggi C. Defining low prognosis patients undergoing assisted reproductive technology: POSEIDON Criteria-The Why. Front Endocrinol (Lausanne). (2018) 9:461. 10.3389/fendo.2018.00461
    1. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. (2006) 113:1210–7. 10.1111/j.1471-0528.2006.01008.x
    1. Kang H. The prevention and handling of the missing data. Korean J Anesthesiol. (2013) 64:402–6. 10.4097/kjae.2013.64.5.402
    1. Hu H, Yao W, Wu Y. The robust em-type algorithms for log-concave mixtures of regression models. Comput Stat Data Anal. (2017) 111:14–26. 10.1016/j.csda.2017.01.004
    1. Steward RG, Lan L, Shah AA, Yeh JS, Price TM, Goldfarb JM, et al. . Oocyte number as a predictor for ovarian hyperstimulation syndrome and live birth: an analysis of 256,381 in vitro fertilization cycles. Fertil Steril. (2014) 101:967–73. 10.1016/j.fertnstert.2013.12.026
    1. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. (2011) 26:1768–74. 10.1093/humrep/der106
    1. Alviggi C, Conforti A, Santi D, Esteves SC, Andersen CY, Humaidan P, et al. . Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis. Hum Reprod Update. (2018) 24:599–614. 10.1093/humupd/dmy019
    1. Casarini L, Pignatti E, Simoni M. Effects of polymorphisms in gonadotropin and gonadotropin receptor genes on reproductive function. Rev Endocr Metab Disord. (2011) 12:303–21. 10.1007/s11154-011-9192-2
    1. Conforti A, Esteves SC, Di Rella F, Strina I, De Rosa P, Fiorenza A, et al. The role of recombinant LH in women with hypo-response to controlled ovarian stimulation: a systematic review and meta-analysis. Reprod Biol Endocrinol. (2019) 17:18 10.1186/s12958-019-0475-x
    1. La Marca A, Papaleo E, Alviggi C, Ruvolo G, De Placido G, Candiani M, et al. . The combination of genetic variants of the FSHB and FSHR genes affects serum FSH in women of reproductive age. Hum Reprod. (2013) 28:1369–74. 10.1093/humrep/det061
    1. Riccetti L, De Pascali F, Gilioli L, Santi D, Brigante G, Simoni M, et al. . Genetics of gonadotropins and their receptors as markers of ovarian reserve and response in controlled ovarian stimulation. Best Pract Res Clin Obstet Gynaecol. (2017) 44:15–25. 10.1016/j.bpobgyn.2017.04.002
    1. Simoni M, Casarini L. Mechanisms in endocrinology: genetics of FSH action: a 2014-and-beyond view. Eur J Endocrinol. (2014) 170:R91–107. 10.1530/EJE-13-0624
    1. Wunsch A, Sonntag B, Simoni M. Polymorphism of the FSH receptor and ovarian response to FSH. Ann D'endocrinol. (2007) 68:160–6. 10.1016/j.ando.2007.04.006
    1. Teixeira DM, Martins WP. The two sides of the individualization of controlled ovarian stimulation. Hum Reprod Update. (2014) 20:614. 10.1093/humupd/dmu013
    1. McLernon DJ, Steyerberg EW, Te Velde ER, Lee AJ, Bhattacharya S. Predicting the chances of a live birth after one or more complete cycles of in vitro fertilisation: population based study of linked cycle data from 113 873 women. BMJ. (2016) 355:i5735. 10.1136/bmj.i5735
    1. Nelson SM, Lawlor DA. Predicting live birth, preterm delivery, and low birth weight in infants born from in vitro fertilisation: a prospective study of 144,018 treatment cycles. PLoS Med. (2011) 8:e1000386. 10.1371/journal.pmed.1000386
    1. Porcu G, Lehert P, Colella C, Giorgetti C. Predicting live birth chances for women with multiple consecutive failing IVF cycles: a simple and accurate prediction for routine medical practice. Reprod Biol Endocrinol. (2013) 11:1. 10.1186/1477-7827-11-1
    1. Arvis P, Lehert P, Guivarc'h-Leveque A. Simple adaptations to the Templeton model for IVF outcome prediction make it current and clinically useful. Hum Reprod. (2012) 27:2971–8. 10.1093/humrep/des283
    1. van Loendersloot LL, van Wely M, Repping S, van der Veen F, Bossuyt PM. Templeton prediction model underestimates IVF success in an external validation. Reprod Biomed Online. (2011) 22:597–602. 10.1016/j.rbmo.2011.02.012
    1. La Marca A, Grisendi V, Giulini S, Sighinolfi G, Tirelli A, Argento C, et al. . Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study. J Assist Reprod Genet. (2015) 32:931–7. 10.1007/s10815-015-0476-4
    1. Yang Y, Sun X, Cui L, Sheng Y, Tang R, Wei D, et al. . Younger poor ovarian response women achieved better pregnancy results in the first three IVF cycles. Reprod Biomed Online. (2016) 32:532–7. 10.1016/j.rbmo.2016.02.013
    1. Baruffi RL, Mauri AL, Petersen CG, Felipe V, Martins AM, Cornicelli J, et al. . Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a meta-analysis. Reprod Biomed Online. (2007) 14:14–25. 10.1016/S1472-6483(10)60758-4
    1. Hill MJ, Levens ED, Levy G, Ryan ME, Csokmay JM, DeCherney AH, et al. . The use of recombinant luteinizing hormone in patients undergoing assisted reproductive techniques with advanced reproductive age: a systematic review and meta-analysis. Fertil Steril. (2012) 97:1108 e1101–14. 10.1016/j.fertnstert.2012.01.130
    1. Hill MJ, Levy G, Levens ED. Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature. Reprod Biomed Online. (2012) 24:261–71. 10.1016/j.rbmo.2011.12.005
    1. Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J, et al. . Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update. (2007) 13:445–52. 10.1093/humupd/dmm008
    1. Konig TE, van der Houwen LE, Lambalk CB. Recombinant LH supplementation in women of 35 years and older undergoing IVF? Fertil Steril. (2012) 98:e10–11; author reply e12. 10.1016/j.fertnstert.2012.04.048
    1. Konig TE, van der Houwen LE, Overbeek A, Hendriks ML, Beutler-Beemsterboer SN, Kuchenbecker WK, et al. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study. Hum Reprod. (2013) 28:2804–12. 10.1093/humrep/det266
    1. van Wely M, Kwan I, Burt AL, Thomas J, Vail A, Van der Veen F, et al. . Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. A Cochrane review. Hum Reprod Update. (2012) 18:111. 10.1093/humupd/dmr048
    1. Santi D, Casarini L, Alviggi C, Simoni M. Efficacy of follicle-stimulating hormone (FSH) alone, FSH + luteinizing hormone, human menopausal gonadotropin or FSH + Human chorionic gonadotropin on assisted reproductive technology outcomes in the “personalized” medicine era: a meta-analysis. Front Endocrinol (Lausanne). (2017) 8:114 10.3389/fendo.2017.00114
    1. Casarini L, Lispi M, Longobardi S, Milosa F, La Marca A, Tagliasacchi D, et al. . LH and hCG action on the same receptor results in quantitatively and qualitatively different intracellular signalling. PLoS ONE. (2012) 7:e46682. 10.1371/journal.pone.0046682
    1. Casarini L, Riccetti L, De Pascali F, Gilioli L, Marino M, Vecchi E, et al. . Estrogen modulates specific life and death signals induced by LH and hCG in human primary granulosa cells in vitro. Int J Mol Sci. (2017) 18:926. 10.3390/ijms18050926

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera